Logo image of CTKB

CYTEK BIOSCIENCES INC (CTKB) Stock Fundamental Analysis

NASDAQ:CTKB - Nasdaq - US23285D1090 - Common Stock - Currency: USD

4.17  +0.14 (+3.47%)

After market: 4.17 0 (0%)

Fundamental Rating

4

Taking everything into account, CTKB scores 4 out of 10 in our fundamental rating. CTKB was compared to 54 industry peers in the Life Sciences Tools & Services industry. CTKB has a great financial health rating, but its profitability evaluates not so good. CTKB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CTKB had negative earnings in the past year.
CTKB had a positive operating cash flow in the past year.
In multiple years CTKB reported negative net income over the last 5 years.
Of the past 5 years CTKB 4 years had a positive operating cash flow.
CTKB Yearly Net Income VS EBIT VS OCF VS FCFCTKB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

With a Return On Assets value of -2.33%, CTKB perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
CTKB has a Return On Equity of -2.96%. This is comparable to the rest of the industry: CTKB outperforms 59.26% of its industry peers.
Industry RankSector Rank
ROA -2.33%
ROE -2.96%
ROIC N/A
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
CTKB Yearly ROA, ROE, ROICCTKB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

Looking at the Gross Margin, with a value of 54.94%, CTKB is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
In the last couple of years the Gross Margin of CTKB has grown nicely.
CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
CTKB Yearly Profit, Operating, Gross MarginsCTKB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTKB has less shares outstanding
Compared to 5 years ago, CTKB has less shares outstanding
Compared to 1 year ago, CTKB has a worse debt to assets ratio.
CTKB Yearly Shares OutstandingCTKB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CTKB Yearly Total Debt VS Total AssetsCTKB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CTKB has an Altman-Z score of 3.86. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CTKB (3.86) is better than 77.78% of its industry peers.
CTKB has a debt to FCF ratio of 0.28. This is a very positive value and a sign of high solvency as it would only need 0.28 years to pay back of all of its debts.
The Debt to FCF ratio of CTKB (0.28) is better than 90.74% of its industry peers.
CTKB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CTKB has a better Debt to Equity ratio (0.00) than 74.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.28
Altman-Z 3.86
ROIC/WACCN/A
WACC10.57%
CTKB Yearly LT Debt VS Equity VS FCFCTKB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

CTKB has a Current Ratio of 5.62. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB has a Current ratio of 5.62. This is in the better half of the industry: CTKB outperforms 77.78% of its industry peers.
CTKB has a Quick Ratio of 4.95. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.95, CTKB is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.95
CTKB Yearly Current Assets VS Current LiabilitesCTKB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.05% over the past year.
CTKB shows a small growth in Revenue. In the last year, the Revenue has grown by 3.85%.
CTKB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.19% yearly.
EPS 1Y (TTM)45.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)3.85%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%-2.18%

3.2 Future

Based on estimates for the next years, CTKB will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.83% on average per year.
CTKB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.34% yearly.
EPS Next Y-343.7%
EPS Next 2Y-80.67%
EPS Next 3Y-26.83%
EPS Next 5YN/A
Revenue Next Year-2.46%
Revenue Next 2Y2.57%
Revenue Next 3Y6.34%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CTKB Yearly Revenue VS EstimatesCTKB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
CTKB Yearly EPS VS EstimatesCTKB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTKB. In the last year negative earnings were reported.
Also next year CTKB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTKB Price Earnings VS Forward Price EarningsCTKB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CTKB indicates a somewhat cheap valuation: CTKB is cheaper than 70.37% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 30.46
EV/EBITDA N/A
CTKB Per share dataCTKB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as CTKB's earnings are expected to decrease with -26.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-80.67%
EPS Next 3Y-26.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTKB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (8/13/2025, 4:30:01 PM)

After market: 4.17 0 (0%)

4.17

+0.14 (+3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners60.35%
Inst Owner Change0.08%
Ins Owners9.19%
Ins Owner Change1.41%
Market Cap528.17M
Analysts78.18
Price Target5.87 (40.77%)
Short Float %4.91%
Short Ratio4.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.05%
Min EPS beat(2)-96.08%
Max EPS beat(2)31.98%
EPS beat(4)2
Avg EPS beat(4)-15.05%
Min EPS beat(4)-161.44%
Max EPS beat(4)165.36%
EPS beat(8)3
Avg EPS beat(8)103.04%
EPS beat(12)6
Avg EPS beat(12)76.91%
EPS beat(16)8
Avg EPS beat(16)70.04%
Revenue beat(2)0
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)-4.73%
Revenue beat(4)0
Avg Revenue beat(4)-4.49%
Min Revenue beat(4)-7.72%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-3.1%
Revenue beat(12)3
Avg Revenue beat(12)-5.19%
Revenue beat(16)7
Avg Revenue beat(16)-2.84%
PT rev (1m)0%
PT rev (3m)-14.18%
EPS NQ rev (1m)-16.67%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-335%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-4.15%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-3.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.68
P/FCF 30.46
P/OCF 24.8
P/B 1.39
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)0.14
FCFY3.28%
OCF(TTM)0.17
OCFY4.03%
SpS1.56
BVpS3
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.33%
ROE -2.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.94%
FCFM 8.8%
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
F-Score6
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.28
Debt/EBITDA N/A
Cap/Depr 33.9%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.62
Quick Ratio 4.95
Altman-Z 3.86
F-Score6
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)161.41%
Cap/Depr(5y)218.84%
Cap/Sales(3y)3.46%
Cap/Sales(5y)3.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-343.7%
EPS Next 2Y-80.67%
EPS Next 3Y-26.83%
EPS Next 5YN/A
Revenue 1Y (TTM)3.85%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%-2.18%
Revenue Next Year-2.46%
Revenue Next 2Y2.57%
Revenue Next 3Y6.34%
Revenue Next 5YN/A
EBIT growth 1Y6.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.94%
EBIT Next 3Y53.35%
EBIT Next 5YN/A
FCF growth 1Y199.14%
FCF growth 3Y331.22%
FCF growth 5YN/A
OCF growth 1Y369.92%
OCF growth 3Y76.32%
OCF growth 5YN/A